

Indonesia's 1Q GDP misses estimates but a rebound is coming

Indonesia's economy contracted 0.7% year-on-year in the first quarter as domestic demand stayed soft



Source: Stenly Lam


-0.7% 1Q GDP growth (year-on-year)

Lower than expected

1Q GDP posts year-on-year contraction of 0.7%

Indonesia's economy shrank modestly in the first three months of the year, lower by 0.7% compared to 1Q 2020 and down 0.96% compared to the previous quarter. A spate of natural calamities and a spike in Covid-19 infections at the start of the year scuttled hopes for a strong pick-up in economic activity, prompting authorities to allocate more funds to fiscal stimulus to bolster the recovery. Domestic demand remained soft, as evidenced by disappointing retail sales data (-17.1% as of March) reported by the central bank while also manifesting in subdued core inflation which is averaging 1.4% for the year (vs 2.3% in 2020). Authorities have retained their official growth estimate for the year, with GDP expected to settle between 4.3-5.3% although Bank Indonesia (BI) recently trimmed ITS forecast to 4.1-5.1% likely due to the 1Q performance.

Indonesia GDP growth



Turning the corner?

Indonesia continues to bet on an aggressive vaccination rollout to help boost the economic recovery with more than 20 million doses administered as of 4 May. As more and more citizens receive their vaccines, we can expect consumer demand to recover somewhat to help drive a rebound in GDP in the second half of the year. Prospects for a rebound in GDP are also noted in improving export performance (up 30.7% in March) as well as surging manufacturing activity with the latest IHS Markit PMI manufacturing index hitting the highest level to date. [We continue to expect better growth numbers from Indonesia](#) with prospects for faster growth tied largely to the vaccination efforts. Increased protection from the vaccine will help stimulate domestic demand while manufacturing activity will also likely continue to expand as global trade improves and exports pickup. The potent mix of fiscal and monetary stimulus alongside the vaccination rollout should translate to an overall improving growth outlook in the coming quarters.

Author

Nicholas Mapa

Senior Economist, Philippines

nicholas.antonio.mapa@asia.ing.com

Disclaimer

This publication has been prepared by the Economic and Financial Analysis Division of ING Bank N.V. ("ING") solely for information purposes without regard to any particular user's investment objectives, financial situation, or means. *ING forms part of ING Group (being for this purpose ING Group N.V. and its subsidiary and affiliated companies).* The information in the publication is not an investment recommendation and it is not investment, legal or tax advice or an offer or solicitation to purchase or sell any financial instrument. Reasonable care has been taken to ensure that this publication is not untrue or misleading when published, but ING does not represent that it is accurate or complete. ING does not accept any liability for any direct, indirect or consequential loss arising from any use of this publication. Unless otherwise stated, any views, forecasts, or estimates are solely those of the author(s), as of the date of the publication and are subject to change without notice.

The distribution of this publication may be restricted by law or regulation in different jurisdictions and persons into whose possession this publication comes should inform themselves about, and observe, such restrictions.

Copyright and database rights protection exists in this report and it may not be reproduced, distributed or published by any person for any purpose without the prior express consent of ING. All rights are reserved. ING Bank N.V. is authorised by the Dutch Central Bank and supervised by the European Central Bank (ECB), the Dutch Central Bank (DNB) and the Dutch Authority for the Financial

Markets (AFM). ING Bank N.V. is incorporated in the Netherlands (Trade Register no. 33031431 Amsterdam). In the United Kingdom this information is approved and/or communicated by ING Bank N.V., London Branch. ING Bank N.V., London Branch is authorised by the Prudential Regulation Authority and is subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority. ING Bank N.V., London branch is registered in England (Registration number BR000341) at 8-10 Moorgate, London EC2 6DA. For US Investors: Any person wishing to discuss this report or effect transactions in any security discussed herein should contact ING Financial Markets LLC, which is a member of the NYSE, FINRA and SIPC and part of ING, and which has accepted responsibility for the distribution of this report in the United States under applicable requirements.

Additional information is available on request. For more information about ING Group, please visit <http://www.ing.com>.